Ligand Pharmaceuticals, Inc. (LGND)
280.18
-6.11
(-2.13%)
USD |
NASDAQ |
Aug 24, 16:00
280.04
-0.14
(-0.05%)
After-Hours: 20:00
Ligand Pharmaceuticals Gross Profit Margin (Quarterly) : 82.24% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 82.24% |
| March 31, 2026 | 78.02% |
| December 31, 2025 | 81.42% |
| September 30, 2025 | 89.70% |
| June 30, 2025 | 76.56% |
| March 31, 2025 | 71.09% |
| December 31, 2024 | 74.08% |
| September 30, 2024 | 79.33% |
| June 30, 2024 | 73.12% |
| March 31, 2024 | 64.27% |
| December 31, 2023 | 64.57% |
| September 30, 2023 | 64.54% |
| June 30, 2023 | 62.93% |
| March 31, 2023 | 72.99% |
| December 31, 2022 | 40.23% |
| September 30, 2022 | 61.59% |
| June 30, 2022 | 58.64% |
| March 31, 2022 | 54.68% |
| December 31, 2021 | 63.72% |
| September 30, 2021 | 64.10% |
| June 30, 2021 | 50.34% |
| March 31, 2021 | 62.89% |
| December 31, 2020 | 65.65% |
| September 30, 2020 | 75.56% |
| June 30, 2020 | 72.73% |
| Date | Value |
|---|---|
| March 31, 2020 | 66.30% |
| December 31, 2019 | 11.22% |
| September 30, 2019 | 73.00% |
| June 30, 2019 | 76.35% |
| March 31, 2019 | 83.07% |
| December 31, 2018 | 89.20% |
| September 30, 2018 | 84.27% |
| June 30, 2018 | 95.07% |
| March 31, 2018 | 92.76% |
| December 31, 2017 | 88.64% |
| September 30, 2017 | 84.75% |
| June 30, 2017 | 87.11% |
| March 31, 2017 | 89.56% |
| December 31, 2016 | 85.26% |
| September 30, 2016 | 82.86% |
| June 30, 2016 | 82.58% |
| March 31, 2016 | 88.27% |
| December 31, 2015 | 95.83% |
| September 30, 2015 | 89.59% |
| June 30, 2015 | 85.88% |
| March 31, 2015 | 92.64% |
| December 31, 2014 | 82.60% |
| September 30, 2014 | 90.01% |
| June 30, 2014 | 88.82% |
| March 31, 2014 | 84.64% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Johnson & Johnson | 68.73% |
| Eli Lilly & Co. | 85.78% |
| Merck & Co., Inc. | 71.51% |
| Zevra Therapeutics, Inc. | 95.36% |
| Liquidia Corp. | 93.10% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 20.71% |
| Return on Assets | 12.80% |
| Return on Invested Capital | 13.60% |
| Profit Margin (Quarterly) | 76.16% |
| Operating Margin (Quarterly) | 13.49% |
| Return on Net Operating Assets | 32.65% |